Feasibility and safety of perioperative entrectinib in a patient with ROS1-positive locally advanced NSCLC: A case report

Abstract

NSCLC with ROS1 fusion mutations represents a rare mutation subtype, making it challenging to conduct randomized controlled studies. Here, we report the case of a patient with stage IIIA (cT2aN2M0) ROS1 fusion lung adenocarcinoma who achieved downstaging and completed resection after a 3-month treatment with entrectinib, resulting in a postoperative pathological stage of ypT1cN0M0. The patient continued adjuvant entrectinib therapy and has remained recurrence-free during follow-up, with 21 months since diagnosis and 18 months since surgery.